ABSTRACT
INTRODUCTION
Interest in understanding the process of new blood vessel formation, or angiogenesis, stems from the desire and need to understand the etiology of processes of wound healing, tissue development and repair, and especially pathological neovasculanzation events of solid tumor growth. The available models of angiogenesis that have been proposed (I-4) point to prohferative capability of endothelial cells, the principal cell type lining the inner walls of blood vessels, in forming capillary tubes in response to stimulus. This stimulus may be a chemoattractant which plays a pivotal role in proliferation and migration of endothelial cells (5, 6) . Essential to this migration process is secretion of proteases by endothelial cells which subsequently degrade the basement membrane (7, 8) . This process, the basis of angiogenic events, leads to sprouting of capillaries by outgrowth and invasion by endothelial cells. The release of angiogenic factors is an important stimulus in this process. In this context, the understanding of the regulation and control of expression of genes for angiogenic factors is crucial, i.e. under what physiological conditions are the promoters of these genes upregulated? What are the cis-and trans-acting regulatory elements involved in such a process? With this basic knowledge we can begin to identify the molecular events, particularly signal transduction pathways or transcnptional factors, that may subsequently play a critical role in angiogenesis.
Several angiogenic factors have been described (9, 10) . One of these angiogenic factors is acidic Fibroblast growth factor (aFGF) This growth factor, onginally called endothelial cell growth factor because of its mitogenic effect on these cells (11) , is a single chain polypeptide of 155 amino acids and has a molecular mass * To whom correspondence should be addressed of 17 kDa. aFGF belongs to the fibroblast growth factor (FGF) family (12) , which now consists of nine members (12) (13) (14) (15) (16) , with aFGF classified as fibroblast growth factor 1 (FGF-1). It is a mitogen for a variety of mesenchymaJ and neuroectodermal cells (12, 17) . Particularly, FGF-1 is a mitogen for cultured vascular endothelial cells and an angiogenic factor in vivo (18) It also has a role in heart development (19) , vasodilation (20) , tissue repair, wound healing and pathological angiogenic events, especially neovascularization of solid tumors (9, 21) .
The human FGF-1 gene spans over 100 kbp and contains three protein coding exons and four upstream untranslated exons designated -1 A, -1B, -1C, and -1D (22) (23) (24) (25) (26) (27) . Splicing of -1 A, -1B, -1C, or -ID to the first protein coding exon generates l.A, l.B, l.C, and l.DmRNAs respectively These variant forms of FGF-1 mRNA are expressed in a tissue-specific manner. FGF-l.A mRNA is the predominant species in kidney, whereas FGF-l.B mRNA is the predominant species in brain (26) . Furthermore, using RNase protection assays we demonstrated that the FGF-1 transcript expressed in U1242MG and D65MG ghoblastoma cell lines is neither l.A, l.B nor l.C, suggesting the existence of a fourth untranslated exon (27) . We describe here the strategy employed to identify this fourth untranslated exon along with the distribution of this fourth variant of FGF-1 mRNA. The transcription start sites of this promoter have been mapped by RNase protection and a single-strand nuclease-sensitive site within this region has been localized.
FGF-1 and FGF-2 expression in human vascular smooth muscle cells cultured in vitro has been previously reported (28) (29) (30) (31) . Using Northern blot analyses, Winkles and Gay (32) previously reported significant induction of FGF-1 transcripts in vascular smooth muscle cells treated with fetal bovine serum (FBS) or phorbol 12-mynstate 13-acetate (PMA) Here we confirm these previous results by a more sensitive RNAse protection assay and show that the promoter 1C is responsive to these stimuli. Moreover, the FGF-l.C transcription start site is determined by RNase protection analysis. Taken together, these results point to mechanisms of up-regulation of FGF-1 transcripts in vascular smooth muscle cells and have implications in understanding atherosclerosis and hypertension, wound healing and tissue repair processes, and also inflammatory responses.
MATERIALS AND METHODS

Genomic Southern blotting
Genomic DNA from mouse, rat, sheep, and rabbit was provided by Dr Yung Yu, and mouse NIH 3T3 DNA was provided by Dr Linda Ernst, both at The Ohio State University. DNA from other species was isolated by homogenizing tissue in digestion buffer (10 mM Tris, pH 8.0,100 mM NaCI, 25 mM EDTA, pH 8.0,0.5% SDS). The homogenate was incubated for 18 h at 55°C in digestion buffer plus 0.1 mg/ml proteinase K. After ethanol precipitation, the high molecular weight DNA was spooled by a glass rod. Twenty (ig of genomic DNA from various species was digested with appropriate restriction enzymes and separated on a 0.8% agarose gel. The DNA was transferred to a nylon filter (Hybond-N, Amersham) and processed for blotting (33) . A 1.2 kbp EcoRl-BgH\ fragment, 6.6 kbp upstream from the first protein coding exon (22) , was used to generate a 32 P-labeled probe (Multiprime DNA labeling system, Amersham). The filter was pre-hybridized in 40% formamide, 6 x SSPE (0.9 M NaCI, 60 mM NaH 2 PO 4 , 20 mM EDTA, pH 7.4), 3% SDS, 0.5% powdered milk for 12 h at42°C. Hybridization was performed at 42°C with 1 x 10 6 c.p.mVml probe in hybridization buffer (prehybridization buffer plus 10% dextran sulfate) for 40 h at 42°C. Reduced stringency washes were performed initially [2 x SSC (0 3 M NaCI, 30 mM Na citrate, pH 7.0), 0.5% SDS (2x, room temperature, 15 min); 2 x SSC, 0.5% SDS (2x, 55°C, 15 min)]. Subsequently, the filter was washed in 0.5 x SSC, 0.1% SDS (2x, 55 °C, 15 min), and finally under high stringency in 0.1 x SSC, 0.1 % SDS (2x, 55 °C, 15 min). The results were visualized by autoradiography after each set of washes.
Tissues and cell lines
The human tissues used in this study were obtained from the 
Reverse transcription and polymerase chain reaction (RT-PCR)
RNA was isolated from tissues, cell lines and cultured cells using the guanidinium thiocyanate and cesium chloride gradient method (34) . Complementary DNA was synthesized from 1 u.g of total cellular RNA using avian myeloblastosis virus (AMV) reverse transcriptase, oligo(dT)i2-i8 and random hexamers. After heating at 95 °C for 5 min, 3 fxl of the cDNA reaction was amplified in a 50 uJ PCR reaction for 35 cycles. The parameters were: denaturation at 94°C for 30 s, annealing at 48°C for 45 s, and extension at 72°C for 1 min. Primers (HBGF 1702 and HBGF 151 in ref. 26 ) used were derived from sequences of the first and second protein coding exons of human FGF-1 and unique sequences upstream of a putative splice donor sequence identified in the 1.2 kbp EcoRl-Bg[U fragment 6.6 kbp upstream from the first coding exon. The PCR product was analyzed on a 2% Nusieve and 1 % Seakem (FMC BioProducts, Rockland, ME) agarose gel and visualized by staining with ethidium bromide. The amplified fragment was cloned into £coRV-digested, T-tailed pBluescnpt KS(+) as described by Marchuk et al (35) .
Generation of FGF-l.C and l.D minigenes
The FGF-l.C minigene was generated by subcloning into pBluescnpt KS(+) a 184 bp Pstl-BamHl fragment from a 299 bp RT-PCR-generated FGF-l.C cDNA clone (27) . A 340 bp Pst\ fragment isolated from cloned FGF-1 genomic DNA was then subcloned into the Pst\ site to provide sequence 5' to the -1C exon. The resultant minigene was then digested with EcoRl and used as a template to generate a nboprobe for use in RNase protection assays . Genomic fragments and cDNA clones were sequenced by Sanger's dideoxy nucleotide chain termination method (36) using double-stranded and single-stranded DNA templates (37) , with T3 and T7 primers (United States Biochemicals, Cleveland, OH). A computer program (DNA Star Inc., Madison, WI) was used to search for the splice donor consensus sequence GTRAGT. FGF-ID homology searches were performed using the FASTA program (38) .
RNase protection assays
RNA isolated from tissue and cell lines/cultured cells was checked for integrity on a formaldehyde-containing agarose gel and visualized by staining with ethidium bromide. A -^P-Iabeled antisense nboprobe was derived from FGF-1 .D cDNA by in vitro transcription. The probe included 39 nt of known FGF-ID sequence spliced to 203 bp of the first and 7 bp of the second protein coding exons (26) . Twenty to forty jig of RNA and antisense riboprobe (5 x 10 5 c.p.m.) were denatured at 85 °C for 5 min and hybridized in 30 uJ of 80% formamide, 0.4 M NaCl, 1 mM EDTA, 40 mM PIPES (pH 6.4) at 42°C for 18 h. Samples were digested with RNase A (7-20 (ig/ml) and Tl (0.35-1 (lg/ml) for 60 nun at 30°C, and analyzed on a 6% denaturing polyacrylarrude gel. RNA isolated from HeLa, Hep G2, and Nairn 6 cell lines was provided by Dr Lai chu Wu, The Ohio State University. U937 (± y-interferon) and K562 RNA was provided by Dr Linda Ernst, The Ohio State University. A 780 bp Pstl-Xbal human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA fragment was subcloned in pBluescnpt KS(+) and used to generate an anti-sense riboprobe. Autoradiograms were scanned with an LKB-Bromma laser densitometer or a Betagen scanner.
Single-strand nuclease treatment of plasmid DNA
Supercoiled plasmid DNA containing the 1.2 kbp EcoRl-Bglll fragment having the FGF-1 exon -ID region was treated with mung bean nuclease (Boehnnger Mannheim) at 2 U/^g DNA in buffer containing 30 mM NaOAc, pH 5.0, 50 mM NaCl, 1 mM ZnCl 2 , 5% glycerol v/v in 20 yd volume for 60 min at 37°C. Subsequently, phenol/chloroform/isoamyl alcohol (25:24:1) extraction was performed once, followed by chloroform/isoamyl alcohol (24:1) extraction, and ethanol precipitation. The DNA was digested with various restriction enzymes. Samples were separated by electrophoresis on a 1.2% agarose gel in TBE (100 mM Tns-HCl, 100 mM Na borate, 2 mM EDTA, pH 8.0) and visualized by ethidium bromide staining As a control, supercoiled DNA was treated in the reverse order also, i.e. linearized with £coRI first, and then treated with mung bean nuclease.
RESULTS
The FGF-1 exon -ID region shows a high degree of nucleotide sequence conservation in primates
To search for the fourth FGF-1 transcript, we used DNA fragments upstream from the first coding exon as probes to hybndize to different primate DNA. Conservation of DNA sequences would imply the presence of exon sequences. A 1.4 kbp EcoRl fragment, 10.7 kbp upstream of the first coding exon was previously shown to hybridize to primate DNA (24) . Upon sequencing, no splicing donor sequences were detected. Subsequently, a 1.2 kbp EcoR\-BgM fragment, 6.6 kbp upstream of the first protein coding exon, was also shown to hybridize to pnmate DNA. Figure 1A shows a Southern blot analysis of human and rhesus monkey genomic DNA digested with various restriction enzymes and probed with the 1 2 kbp EcoRl-BglU fragment. The blot was washed under high stringency. The Southern blot in Figure 1B is a Zoo blot using the same probe as in Figure 1 A. The blot was also washed under high stnngency. When washed under reduced stringency, the weak bands detected in non-primate mammals are more easily detectable (data not shown). These data suggest a high degree of conservation of this region in primates, and conservation to a lesser degree in other mammals. Sequence analysis revealed a putative splice donor sequence in this fragment (GenBank accession no. L01488). RT-PCR was subsequently used to isolate a cDNA that was designated FGF-l.D (GenBank accession no. L01487).
The FGF-l.D mRNA is expressed in two glioblastoma cell lines, a prostate carcinoma cell line, two fibroblast eel] lines and vascular smooth muscle cells
In order to identify different cell types expressing FGF-l.D mRNA, RNase protection assays were performed using an FGF-l.D cDNA-derived riboprobe. Representative RNase protection assay results (Fig. 2) indicate that FGF-l.D mRNA is the major FGF-1 transcript in a glioblastoma-derived cell line (U1242MG), an embryo lung fibroblast-derived cell line (M426), and iliac artery smooth muscle cells. The glioblastoma^ierived cell line U1240MG which we previously showed to express predominantly FGF-l.B mRNA (26) was used as a negative control RNase protection assays utilizing riboprobes specific for FGF-l.C and -l.D transcripts demonstrated that the prostate carcinoma-denved cell line PC-3, the ghoblastoma-derived cell line D65MG, the neonatal foreskin fibroblast-derived cell line Saphenous vein smooth muscle cells were grown to sub-confluency and subsequently incubated for 72 h in medium containing 0.5% FBS. Serum-starved cells were treated with 10% serum or PMA (100 ng/ml) for 6 h, the time point which was previously shown to have peak FGF-1 mRNA levels in saphenous vein smooth muscle cells (32) . RNA was isolated and analyzed by an RNase protection assay using an FGF-l.D cDNA-derived riboprobe. GAPDH was used to show the relative loadings of RNA in each lane. Normally growing sub-confluent cells express FGF-l.D mRNA predominantly (data not shown). Serum-starved cells show low levels of FGF-1 .D mRNA (Fig. 3 , lane 1), which is slightly increased (less than 2-fold) after treatment with serum (lane 2) or PMA (lane 3). Furthermore, a significant increase (at least 10-fold) of non-l.D mRNA is observed over FGF-l.D mRNA in the serum-starved state (compare lanes 2 and 3 with lane 1). These data provide evidence that the level of non-l.D mRNA increases significantly in response to extracellular stimuli such as serum and PMA. The response to PMA implies that a protein kinase C-dependent signalling pathway may be involved in the regulation of FGF-1 gene expression. In contrast, serum or PMA treatment for 6 h does not affect FGF-1 mRNA levels in iliac artery smooth muscles cells (data not shown). These data suggest heterogeneity in the cell types in regard to cell surface receptors or intracellular second messenger systems that may lead to increased levels of FGF-1 mRNA. Such variety may be considered a mechanism of regulation that provides specificity to certain cell types exhibiting FGF-1 gene inducibility.
Serum or PMA treatment of cultured saphenous vein smooth muscle cells leads to increased levels of FGF-l.C mRNA
To identify which FGF-1 transcript is increased in response to serum and PMA, RNase protection assays were performed using riboprobes derived from other FGF-1 cDNAs. There is a slight increase in the levels of FGF-1 .A mRNA in response to serum and PMA (Fig. 4A, lanes 3 and 4) , when compared overall to the non-l.A mRNA levels. Similarly, RNase protection analysis using FGF-1 .B cDNA-derived riboprobe showed that the induced FGF-1 transcript is non-l.B (data not shown). In contrast, there is a significant increase in levels of FGF-1 .C mRNA in response to serum and PMA (Fig. 4B, lanes 3 and 4) , when compared to the normally growing and serum-starved cells (lanes 1 and 2), and also to the levels of non-1 .C mRNA. Densitometric scanning of these autoradiograms and normalizing the values to GAPDH suggest the possible existence of a fifth FGF-1 transcript with a different 5' end. However, in all other experiments, we consistently observed FGF-1 .C mRNA as being the major species observed (75-90%) in response to serum and PMA (data not shown; also see Fig. 5A ). We therefore conclude that serum or PMA significantly up-regulate the level of FGF-1.C mRNA.
FGF-l.C mRNA has a unique start site, whereas FGF-l.D mRNA consists of multiple 5' ends
High level expression of FGF-1 .C mRNA in serum-stimulated saphenous vein-derived smooth muscle cells allowed us to use this RNA preparation to map the transcription start site for FGF-l.C. We constructed a mini gene consisting of genomic DNA sequence adjacent to the cDNA sequence utilizing a common Pst\ site. The riboprobe derived from this construct provides an internal control to distinguish FGF-1 .C from non-1 .C transcripts. As shown in Figure 5 A, a single 260 nt fragment was protected, indicating that the FGF-1 .C mRNA has a unique start site positioned 105 bp upstream of the exon -1C splice donor site (Fig. 6A) . Similarly, a recombinant PCR approach was devised to generate a minigene consisting of FGF-1 .D genomic sequences contiguous with the FGF-l.D cDNA. This minigene was used to generate an anti-sense riboprobe and used in an RNase protection assay. Results of this assay (Fig. 5B ) suggest multiple transcription initiation sites positioned at 40 or 57 bp upstream from the exon -ID donor site (Fig. 6B ). These data demonstrate that the two FGF-1 transcripts observed in smooth muscle cells under different growing conditions originate from two distinct promoters of the FGF-1 gene,i.e.FGF-1 promoters ICand lDwhich are 22.4 kbp apart in the FGF-1 gene locus.
A region in the FGF-1 promoter ID sequence is prone to single-strand nuclease breakage in vitro
Having sequenced the 1.2 kbp EcoRl-Bgll\ fragment, we noticed a purine stretch of 72 bp upstream from the FGF-l.D start site. The chromatin conformation may cause this region to become susceptible to single-strand nuclease digestion (39) . Treatment of supercoiled plasmid DNA containing the FGF-1 promoter ID region with mung bean nuclease and subsequent restriction digestion with various enzymes allowed mapping of this single-strand nuclease-sensitive region (Fig. 7) . This region is -950 bp 3' to the EcoRI site, which is immediately upstream from the FGF-l.D start site. Treatment of linearized DNA (digested with EcoRl) with mung bean nuclease did not reveal additional bands other than the linear plasmid DNA. These data indicate an unusual DNA conformation in the 1D promoter region that leads to single-strand exposure which is susceptible to cleavage by single-strand-specific nuclease.
DISCUSSION
In this report we show the distribution of expression of two FGF-1 mRNAs (FGF-l.C and -l.D) in a variety of tissues and cell lines. By using RNase protection assays, we have shown that the two FGF-1 mRNAs are co-expressed, with FGF-l.D mRNA being the major species in glioblastoma U1242 MG cells, lung fibroblasts and iliac artery smooth muscle cells under logarithmically growing conditions (Fig. 2) . The corresponding untranslated exons of the FGF-1 gene that are unique for FGF-1 .C and -l.D mRNAs have been designated exons -1C and -ID, respectively. We further show here that each of these two mRNAs are under the control of its promoter respectively (Fig. 5 ) and that these two promoters are different from the two previously reported (26) . Lastly, promoter 1C is the one that is responsive to stimulation by serum or PMA (Fig. 4) . Our results, taken together, suggest a novel phenomenon observed in the regulation of the FGF-1 gene. In the system used, i.e. saphenous vein smooth muscle cells, normally growing cells utilize promoter 1D. Upon serum or PMA treatment of serum-starved cells, an alternative promoter, 1C, is utilized. Our present findings point to dual promoter usage of the FGF-1 gene in saphenous vein smooth muscle cells.
The nucleotide sequence homology between the human FGF-1 promoter 1C region and the corresponding Syrian hamster sequence has previously been described (27) . Interspecies sequence comparison for the promoter 1D is not possible since the corresponding sequences in other species have not been cloned and sequenced. Comparison of the promoter ID sequence and other published sequences using the FASTA program (38) revealed significant similarity between the 1D promoter and the following genes: 86.5% similarity over 74 bp to the spacer region upstream from the rat rRNA transcription unit (40) , 77.3% similarity over 88 bp to human erythropoietin receptor gene (41) , and 72.5% similarity over 109 bp to murine urokinase plasminogen activator gene (42) . These similarities are essentially in the purine-rich region of these sequences, especially the promoter regions of the human erythropoietin receptor gene (-400 to -313) (41) and the murine urokinase plasminogen activator gene (-211 to -103) (42) . The functional significance of any of these sequences remains to be determined.
There have been several reports of purine-rich regions prone to forming an unusual DNA conformation (39) . Sensitivity of the FGF-1 .D purine stretch to a single-strand-specific nuclease (Fig.  7) suggests it may have an unusual conformation with singlestrand regions. Such a conformation may be a triple helical state whereby two pyrimidine strands share one common purine strand. This sharing of strands is possible for the FGF-1 promoter ID region and is diagrammed in the lower part of Figure 7 . By using monoclonal antibodies to triplex DNA, Burkholder et al. (43) have suggested such regions might be involved in chromatin condensation via interspersed homologous interaction of DNA sequences in chromatin. Furthermore, it was suggested that this triple helical state may be stabilized by non-nucleosomal single-strand DNA binding proteins (43, 44) . Such a region may form a transcriptionally competent complex. In fact, such protein binding has been shown to be involved in transcriptionaJ regulation of the c-myc (45, 46) , epidermal growth factor receptor (47) and c-Ki-ras (48) genes. Additionally, such purine-rich regions can be targets for oligonucleotide-mediated repression of transcription, as shown for c-myc (49) .
Upon searching for putative protein binding sites in the promoter 1D region (1.2 kbp EcoRl-Bgl\\ fragment, GenBank accession no. L01488), there appears to be an AP-1 site, aCArG box, and several PU.l binding sites (27) . The PU.l binding protein, the product of the Spi-l proto-oncogene (50-52) is expressed in macrophages and B cells exclusively. To test for FGF-1 .D mRNA expression, a promonocytic U937 cell line that can be induced to terminal differentiation by y-interferon (53) and a human erythroleukemia K562 cell line were analyzed by RNase protection assay. No expression of FGF-l.D or other FGF-1 mRNA was detected in y-interferon-induced or non-induced U937 cells or in K562 cells. These data, however, do not exclude the possibility that cells of the hematopoietic system may express FGF-1. In fact, Brogi et al. detected immunoreactive FGF-1 in macrophage-rich regions of human atheroma (54) . Whether this FGF-1 is produced by macrophages or is sequestered from neighboring vascular cells remains to be established by in situ hybridization.
The CArG box has been shown to be necessary for regulation of expression of cardiac and skeletal a-actin genes (55, 56) and binds a CArG factor. Furthermore, Boxer et al. (57) have shown that the CArG binding factor is indistinguishable from the c-fos serum response factor. This raises the possibility that promoter ID is activated via the serum response factor and CArG box Heparan sutfate is produced by endothelial cells and has been suggested to regulate vascular smooth muscle cell growth in vivo (62, 63) . This regulation may be via selective inhibition of protein kinase C-dependent signalling pathways involved in gene expression (63, 64) , particularly of growth related genes. It can, therefore, be speculated that deregulation of this anti-proliferative activity of heparin at sites of trauma, for example balloon catheter angioplasty, may affect FGF-1 gene expression. This may subsequently lead to proliferation of vascular smooth muscle cells, leading to a lesion. Such aberrant regulation of proliferation may be the hallmark of the pathological conditions. This hypothesis is consistent with the findings that FGF-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo (65) and the findings that show an increased association of FGF-1 with atherosclerotic plaque microvessels (54) . Using the vascular smooth muscle cells as a model system, it is now possible to test for transcriptional regulation of FGF-1 promoters by heparin. Additionally, in situ hybridizations using FGF-1 .C-and -1 .D-specific probes on affected tissues in these diseases may define which promoters are activated in such pathological sites.
